The findings directly address speculation that the CDC made data reporting errors or intentionally mischaracterized or concealed public health data due to political pressure or interference, said lead author Lori Ann Post.

Why it matters

Accurate data are essential for public health response. Misinterpreting trends can misdirect policy decisions, undermine public trust and distort resource allocation, Post said. 

Despite this episode, the researchers stress that federal mortality data remain the most reliable near real-time source for tracking overdose death.

Long-term opioid prescribing has fallen in the United States over the last decade, but millions of patients still received opioids for 90 days or longer in 2023, according to a new research letter in JAMA led by University of Michigan researchers.

Researchers at the National Institutes of Health (NIH) have identified a novel, highly potent opioid that shows potential as a therapy for both pain and opioid use disorder. In a study published in Nature, the team observed the new drug’s effect in laboratory animals. They showed that it has high pain-relieving effects without causing respiratory depression, tolerance or other indicators of potential for addiction in humans.

In a clinical trial supported by the National Institutes of Health (NIH), a research team found that administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder (OUD) during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue (sublingual), one of the standard methods of treatment. Additionally, serious adverse events were less common in those receiving extended-release treatment. The findings, which support the use of this formulation of buprenorphine for treating OUD during pregnancy, were published in JAMA Internal Medicine.